StockIQpro
NASDAQ:TXG

10x Genomics, Inc.

Track all markets on TradingView
Track all markets on TradingView

10x Genomics, Inc.'s revenue grew 5.2% in fiscal 2025 to $642.8M while operating margin rose to −9.5%, its highest in 9 years. Free cash flow was $130.1M, 20.2% of revenue, and the diluted share count rose 3.6%.Summary generated from 10x Genomics, Inc.'s SEC filings. Latest annual report filed Feb 13, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$642.8M
Revenue growth+5.2%
Revenue, 5-yr CAGR+16.6%
Gross margin69.1%
Operating margin−9.5%
Net margin−6.8%
ROICn/a
Return on equity−5.8%
Debt / equityn/a
Free cash flow$130.1M
FCF margin20.2%
Share count change+3.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue490516619611643
Operating income−52−168−265−195−61
Net income−58−166−255−183−44
Free cash flow−123−165−64−6130

Recent filings

From SEC EDGAR

Peers

Laboratory analytical instruments